Showing 3671-3680 of 9151 results for "".
- Zydus Lifesciences Scores FDA Nod for Generic Acne Drughttps://practicaldermatology.com/news/zydus-lifesciences-scores-fda-nod-for-generic-acne-drug/2461791/The U.S. Food and Drug Administration (FDA) has given its nod to Zydus Lifesciences’ generic antibiotic minocycline hydrochloride extended-release tablets for the treatment of moderate to severe acne in 55 mg, 65 mg, and 115 mg doses, the Company reports. Minocycline hyd
- FDA Nod for Avita Medical’s RECELL for Skin Repigmentation in Vitiligo Patientshttps://practicaldermatology.com/news/fda-nod-for-avita-medicals-recell-for-skin-repigmentation-in-vitiligo-patients/2461787/The U.S. Food and Drug Administration (FDA) has approved AVITA Medical, Inc.’s application for premarket approval (PMA) of its RECELL System for the treatment of vitiligo. RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic d
- EAACI News: Barzolvolimab May Help Tame Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/eaaci-news-barzolvolimab-may-help-tame-chronic-spontaneous-urticaria/2461786/Celldex Therapeutics, Inc.’s barzolvolimab is looking good in chronic spontaneous urticaria, according to data from the Phase 1b single-dose cholinergic cohort included in the chronic inducible urticaria (CIndU) trial that was presented at the European Academy of Allergy and Clini
- Cutera's AviClear Scores FDA Nod as Long-Term Acne Treatmenthttps://practicaldermatology.com/news/cuteras-aviclear-scores-fda-nod-as-long-term-acne-treatment/2461784/The U.S. Food and Drug Administration (FDA) has cleared AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. Cutera’s AviClear initially received FDA clearance for treating acne in March 2022. Now, the FDA has cleared the device for the long
- Vial, Nielsen BioSciences Partner in Phase III Clinical Trial of Candin for Common Wartshttps://practicaldermatology.com/news/vial-nielsen-biosciences-partner-in-phase-iii-clinical-trial-of-candin-for-common-warts/2461783/Vial is partnering with
- Fall Clinical PAs & NP Update: Castle's DecisionDx-SCC Can Identify Tumors Likely to Spread in Low-Risk CSCChttps://practicaldermatology.com/news/fall-clinical-pas-np-update/2461778/Castle Biosciences, Inc.’s DecisionDx-SCC test can identify tumors likely to metastasize in patients with cutaneous squamous cell carcinoma deemed low risk by traditional staging, according to research presented at the the 2023 Fall Clinical Dermatology Conference for PAs &am
- EAACI News: Novel Antibody May Help Treat Melanomahttps://practicaldermatology.com/news/novel-antibody-may-help-treat-melanoma/2461775/A newly discovered antibody may benefit patients with melanoma who do not respond to current immunotherapies, according to a study presented at the Hybrid Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology (EAACI). Unlike
- New RNA Monitoring Method May Allow for Early Diagnosis of AD in Infantshttps://practicaldermatology.com/news/new-rna-monitoring-method-may-allow-for-early-diagnosis-of-ad-in-infants/2461771/A novel monitoring method that enables human skin transcriptome analysis of the mRNA in sebum) collected from the skin using a simple oil-blotting film may help diagnose atopic dermatitis earlier than is currently possible. According to a newstudy
- Novartis Premieres New HS Docuseries at Tribeca Film Festivalhttps://practicaldermatology.com/news/novartis-premieres-new-hs-docuseries-at-tribeca-film-festival/2461768/Novartis is launching a new docuseries, "The Beacons: Illuminating HS Stories, in recognition of Hidradenitis Suppurativa (HS) Awareness Week. The series, which will premiere during the 2023 Tribeca Festival in New York, is part of the "Shine 
- News You Can Use: SID Announces New Research Grant Program Focusing on Type 2 Inflammationhttps://practicaldermatology.com/news/news-you-can-use-sid-announces-new-research-grant-program-focusing-on-type-2-inflammation/2461767/The Society for Investigative Dermatology’s (SID) new research grant program, The SID Type 2 Inflammation Innovation Awards, is open now and the deadline is August 31, 2023